(NASDAQ: NKTR) Nektar Therapeutics's forecast annual revenue growth rate of -8.87% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.49%.
Nektar Therapeutics's revenue in 2026 is $55,633,000.On average, 13 Wall Street analysts forecast NKTR's revenue for 2026 to be $1,489,389,649, with the lowest NKTR revenue forecast at $1,390,633,077, and the highest NKTR revenue forecast at $1,588,044,862. On average, 13 Wall Street analysts forecast NKTR's revenue for 2027 to be $1,274,780,773, with the lowest NKTR revenue forecast at $268,193,522, and the highest NKTR revenue forecast at $1,619,803,732.
In 2028, NKTR is forecast to generate $1,501,045,830 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $4,244,539,200.